ArticleCancer2010
MicroRNA-205-directed transcriptional activation of tumor suppressor genes in prostate cancer.
Article in Cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 141 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
141 citing papers in PubMed, 2 syntheses or guidelines pooled it, 312 citations in OpenAlex.
- Meta-analysis of the differentially expressed microRNA profiles in nasopharyngeal carcinoma.Oncotarget · 2016Pooled it
- Prognostic role of microRNA-205 in multiple human malignant neoplasms: a meta-analysis of 17 studies.BMJ open · 2015Pooled it
- The paradox of nuclear miRNAs: Mechanisms, therapeutic potential, and future directions.Non-coding RNA research · 2026Review
- miR-141-5p positively regulates ACVRL1 expression to promote cervical cancer progression.Human cell · 2026Article
- Bta-miR-30f promotes adipogenesis and unsaturated fatty acid accumulation by targetingiScience · 2026Article
- Intergenerational and transgenerational epigenetic mechanisms shaping livestock production and reproduction.The Journal of reproduction and development · 2026Review
- In Vitro Effects of Cabazitaxel and Menadione on Cell Growth, Metabolism, and Transcriptomic Profile of Human Prostate Cancer Cell Lines.Prostate cancer · 2026Article
- Aging of the human eye lens: Epigenetic landscape and therapeutic targets in age‑related cataracts (Review).International journal of molecular medicine · 2025Review
- NamiRNA-Enhancer Network: The Changing Era Challenge and Chance of miRNA.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- A Brief Review of MicroRNA Profiling in Human Prostate Cancer Tissues and Plasma.Biomolecules · 2025Review
- Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines.Signal transduction and targeted therapy · 2025Review
- Gallic Acid Alleviates Glucolipotoxicity-Induced Nephropathy by miR-709-NFE2L2 Pathway in db/db Mice on a High-Fat Diet.Journal of agricultural and food chemistry · 2024Article
- IL-32/NFκB/miR-205 loop sustains the high expression of IL-32 and enhances the motility of cervical cancer cells.Human cell · 2024Article
- Tetramethylpyrazine ameliorates LPS-induced acute lung injury via the miR-369-3p/DSTN axis.Scientific reports · 2024Article
- Nuclear miRNAs: Gene Regulation Activities.International journal of molecular sciences · 2024Review
- Nuclear miRNAs as transcriptional regulators in processes related to various cancers (Review).International journal of oncology · 2024Review
- Pan-cancer analysis reveals IL32 is a potential prognostic and immunotherapeutic biomarker in cancer.Scientific reports · 2024Article
- Noncanonical functions of microRNAs in the nucleus.Acta biochimica et biophysica Sinica · 2024Review
- miR-617 interacts with the promoter ofFrontiers in oncology · 2024Article
- Bioinformatics-Assisted Extraction of All PCa miRNAs and their Target Genes.MicroRNA (Shariqah, United Arab Emirates) · 2024Article
81 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundMicroRNAs (miRNAs) are small noncoding RNAs that regulate the expression of approximately 60% of all human genes. They play important roles in numerous cellular processes, including development, proliferation, and apoptosis. Currently, it is believed that miRNAs elicit their effect by silencing the expression of target genes. In this study, the authors demonstrated that miRNA-205 (miR-205) induced the expression the interleukin (IL) tumor suppressor genes IL24 and IL32 by targeting specific sites in their promoters.
methodsThe methods used in this study included transfection of small RNAs; quantitative real-time polymerase chain reaction; in situ hybridization; fluorescence-labeled in situ hybridization; cell cycle, apoptosis, cell viability, migratory, clonability, and invasion assays; immunoblotting; and luciferase reporter, nuclear run-on, and chromatin immunoprecipitation assays.
resultsThe results revealed that miR-205 was silenced in prostate cancer. Its re-expression induced apoptosis and cell cycle arrest. It also impaired cell growth, migration, clonability, and invasiveness of prostate cancer cells. Micro-RNA-205 induced the expression of tumor suppressor genes IL24 and IL32 at both the messenger RNA and protein levels. The induction of in vitro transcription and enrichment of markers for transcriptionally active promoters in the IL24 and IL32 genes was observed in response to miR-205.
conclusionsIn this study, a new function for miR-205 was identified that specifically activated tumor suppressor genes by targeting specific sites in their promoters. These results corroborate a newly identified function that miRNAs have in regulating gene expression at the transcriptional level. The specific activation of tumor suppressor genes (eg, IL24, IL32) or other dysregulated genes by miRNA may contribute to a novel therapeutic approach for the treatment of prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.